Wall Street’s push to bring private assets to 401(k)s faces investor apathy: WSJ

Interest in private markets varies sharply by age. Members of Gen Z and Millennials are far more open to investing in private ...

How Rigel Pharmaceuticals’ R289 Trial Progress and FDA Designations Will Impact RIGL Investors

Rigel Pharmaceuticals recently announced the enrollment of the first patient in the dose expansion phase of its ongoing Phase 1b study of R289 in relapsed or refractory lower-risk myelodysplastic ...

Zimmer Biomet Q3 Earnings To Highlight Innovation And Growth - Why I Think It's A Buy

Zimmer Biomet is undervalued despite recent underperformance, backed by innovation, acquisitions, and strong cash flow. Learn ...